Twenty-year time trends in use of evidence-based heart failure drug therapy in Denmark

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Nicklas Vinter
  • Martin Jensen
  • Flemming Skjøth, Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, and Aalborg University Hospital, Aalborg, Denmark., Unit of Epidemiology and Biostatistics, Aalborg University Hospital, Aalborg, Denmark; Clinical Institute, Aalborg University, Denmark.
  • ,
  • Torben Bjerregaard Larsen
  • Lars Frost
  • Søren Paaske Johnsen, Danish Center for Clinical Health Services Research, Department of Clinical Medicine, Aalborg University and Aalborg University Hospital, Aalborg, Denmark.

European guidelines for heart failure (HF) have continuously incorporated new evidence since the first publication in 1995. We aimed to explore time trends in utilisation of pharmacological treatment for HF and dispensing of recommended dosages among patients with a first-time diagnosis of HF. We performed a historical cohort study of patients with a first-time HF diagnosis from 1997 to 2015, identified in the Danish National Patient Registry. Dispensed pharmacological treatment included angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers, mineralocorticoid receptor blockers (MRAs), digoxin and diuretics. Furthermore, we estimated the proportion of patients receiving the recommended target dosages 1 year after the diagnosis. The utilisation increased and correlated with publication of landmark studies, and among patients diagnosed in 2015, approximately two of three received ACEI/ARB and beta-blocker, respectively. Less than half of the patients redeeming prescriptions for ACEIs, ARBs, beta-blockers or MRAs received the recommended target dosages. The utilisation of pharmacological therapy for HF appears to be correlated with the publications of landmark Phase III clinical trials. However, a high proportion of patients do not receive the recommended target dosages. Despite improvements over time, a substantial gap appears to remain between guideline recommendations and pharmacological therapy in routine care.

OriginalsprogEngelsk
TidsskriftBasic & Clinical Pharmacology & Toxicology
ISSN1742-7835
DOI
StatusE-pub ahead of print - 31 jan. 2020
Eksternt udgivetJa

Bibliografisk note

© 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Se relationer på Aarhus Universitet Citationsformater

ID: 178013888